Sartorius Stedim Biotech S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRTOY research report →
Price Chart
About the company
Sartorius Stedim Biotech S. A. , a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry.
- CEO
- Rene Faber
- IPO
- 2022
- Employees
- 10,265
- HQ
- Aubagne, PAC, FR
Get TickerSpark's AI analysis on SRTOY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $232.20B
- P/E
- 66.05
- PEG
- 2.79
- P/S
- 7.01
- P/B
- 4.90
- EV/EBITDA
- 26.20
- Div Yield
- 0.31%
- Gross Margin
- 44.55%
- Op Margin
- 19.36%
- Net Margin
- 10.58%
- ROE
- 7.71%
- ROIC
- 5.95%
Latest fiscal year · YoY change
- Revenue
- $2.85B+2.5%
- Gross Profit
- $1.29B+7.1%
- Op Income
- $527.33M
- Net Income
- $255.12M+45.7%
- EPS
- $0.03-85.6%
- OCF Growth
- -36.5%
- FCF Growth
- -70.6%
- 52W High
- $26.54
- 52W Low
- $17.25
- 50D MA
- $24.12
- 200D MA
- $21.28
- Beta
- 1.14
- RSI (14)
- 44
- Avg Volume
- 58.52K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sartorius said 9M 2026 sales growth and margins were solid, cash flow improved sharply, and it raised full-year outlook for LPS while keeping group and BPS guidance unchanged.· October 22, 2026
- Group operational sales growth was 8.1% constant currency excluding tariff-related customer compensation, versus 6.9% including it.
- Underlying EBITDA margin improved to 30.2% on €828 million of underlying EBITDA, while free cash flow rose 55% to €310 million.
- Bioprocess Solutions continued to recover, with recurring consumables strong and non-recurring equipment orders improving steadily.
- Lab Products and Services posted a very strong Q3; management said part of it was pull-forward/timing, but also saw broad-based underlying improvement.
- Management raised full-year LPS guidance and said the business is benefiting from AI-driven drug discovery, biotech funding recovery, and improving customer CapEx.
For the first 9 months of 2026, group operational sales growth was 8.1% in constant currencies excluding tariff-related customer compensation, or 6.9% including it. Underlying EBITDA was €828 million, up 6.9%, and the margin improved 50 basis points to 30.2%. Underlying net profit increased about 7% to €260 million, and underlying EPS was €3.76 per ordinary share and €3.77 per preference share. Operating cash flow rose to €562 million, free cash flow increased 55% to €310 million, and net debt decreased to €3.68 billion, with net debt/underlying EBITDA at 3.3x. Full-year guidance was confirmed for the group at around the midpoint of 5% to 9% operational sales growth and an underlying EBITDA margin slightly above 30%; BPS guidance remained around the midpoint of 6% to 10% growth and slightly above 32% margin. LPS guidance was raised to growth around the upper end of 2% to 6% and an underlying EBITDA margin slightly above 21%. Management also said it now expects full-year CapEx ratio around 12% for the group, slightly lower than prior, and net debt/underlying EBITDA slightly above 3x at year-end.
Michael Grosse framed the quarter as evidence that Sartorius is progressing on both growth and profitability, with stronger cash generation and balance-sheet deleveraging. He stressed that demand trends remain intact across consumables, equipment recovery is continuing, and the company is seeing meaningful opportunities in AI-driven drug discovery and process intensification. His tone was constructive and confident, but he repeatedly cautioned that Q3’s strong LPS growth should not be extrapolated into Q4.
Florian Funck focused on the mechanics behind the numbers: tariff refunds, customer compensation, margins, and cash. He said the group received €5 million more in U.S. Treasury refunds in Q3, bringing 9M receipts to €31 million out of roughly €40 million claimed, and noted customer compensation reduced sales growth by around 120 basis points in 9M. He highlighted underlying EBITDA of €828 million, free cash flow of €310 million, and leverage improvement to 3.3x, while also flagging that net debt fell to €3.68 billion and the equity ratio improved to 42.8%.
Analysts pressed on bioprocess demand, the equipment recovery, AI-driven drug discovery, U.S. reshoring, single-use bioreactor competition, China, and the size of the LPS Q3 pull-forward. Management said recurring consumables remained strong, equipment recovery was broad-based, and it sees good visibility for the rest of the year; it also said Q3 LPS strength reflected both real underlying demand and timing effects, not a one-off tender. On competition and capacity, management argued its focus is on lower-volume, higher-mix applications where intensified single-use workflows fit customer needs, while also saying there is no plan to delist Sartorius Stedim Biotech and that the reporting reorganization is meant to simplify structure, not change ownership or transparency.
The call showed broad-based revenue momentum, with consumables still healthy, equipment recovery advancing, and LPS benefiting from stronger biotech funding and AI-related workflows. Management also sounded more confident on cash generation and deleveraging, while raising LPS guidance and confirming the group’s profitability outlook.
Management repeatedly warned that Q3’s strong LPS growth included pull-forward and timing effects and should not be treated as a new run rate. Tariff surcharges flipped from a tailwind to a headwind, Q4 faces a tougher comparison base, and equipment recovery is still described as progressing rather than fully normalized. There is also uncertainty around the timing of the remaining tariff refunds and around how much of the current demand improvement is sustainable into 2027 and 2028.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 2.9%
- Shares Outstanding
- 9.73B
- Float Shares
- 277.79M
Our SRTOY coverage
Recent articles, reports, and earnings notes.
No research on SRTOY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SRTOY report →Sartorius Stedim Biotech S.A. (SRTOY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 22
Sartorius Stedim Biotech S.A. (SRTOY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.